Anti-malignin antibody in serum and other tumor marker determinations in breast cancer

Cancer Lett. 2000 Jan 1;148(1):39-48. doi: 10.1016/s0304-3835(99)00297-9.

Abstract

In this study, 154 healthy volunteers and 76 patients were tested using the anti-malignin antibody in serum (AMAS) test. Of the 154 volunteers, three were AMAS positive. After further examination, two were positive for cancer and one had a history of ulcerative colitis. Tumor biopsies of 43 suspicious mammography patients revealed that 32 were cancerous and 11 were benign by pathology. For the cancer patients, 31/32 were positive for the AMAS test, while 4/11 of the pathological benign cases were AMAS positive. In comparison to cancer antigen tests, AMAS was more sensitive (97%) in detecting breast cancer than CEA (0%), CA 15-3 (10%), CA 19-5 (5%) or CA 125 (16%) in the same patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Neoplasm / blood*
  • Antibodies, Neoplasm / immunology
  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / immunology
  • Biopsy
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery
  • Carcinoembryonic Antigen / blood
  • Carcinoma in Situ / diagnosis
  • Carcinoma in Situ / immunology
  • Carcinoma in Situ / pathology
  • Evaluation Studies as Topic
  • False Negative Reactions
  • False Positive Reactions
  • Female
  • Humans
  • Male
  • Mammography
  • Middle Aged
  • Neoplasm Proteins / immunology*
  • Neoplasm, Residual / diagnosis
  • Neoplasm, Residual / immunology
  • Neoplasm, Residual / pathology
  • Sensitivity and Specificity
  • Treatment Outcome

Substances

  • Antibodies, Neoplasm
  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Neoplasm Proteins
  • malignin